ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Global ICIs Market Exceeds USD 30 Billion in 2021, with its Number and Indications Approved Entering an Outbreak Period
April 11, 2022Lately, Opdualag, a fixed-dose compound preparation of BMS consisting of LAG-3 inhibitor relatlimab and PD-1 monoclonal antibody nivolumab, was approved by FDA for the treatment of adults and pediatric patients aged 12 years and older with unresectable or -
BMS’ Opdivo plus LAG-3 antibody relatlimab show promise in melanoma
March 31, 2021Bristol Myers Squibb (BMS) has revealed top-line data from a Phase II/III trial evaluating its PD-1 inhibitor Opdivo plus its investigational anti-LAG-3 antibody relatlimab in previously untreated metastatic or unresectable melanoma.
Pharma Sources Insight January 2025
